Watching Monopar Therapeutics Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planFunding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Back to SEC FilingsReg FD DisclosureItem 7.01 · 8-KMEDIUM RiskPositive
Monopar Therapeutics Inc.
Monopar TherapeuticsFiled: Jul 22, 2026CIK: 0001645469Biotechnology
AI Executive Summary
AI-powered analysis of 8-K filing content
Monopar Therapeutics initiated a rolling submission of a New Drug Application to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease treatment, representing a significant milestone in advancing a rare disease therapeutic to market.
Key Takeaways
Rolling NDA submission for ALXN1840 began on July 22, 2026, accelerating the FDA review process
ALXN1840 targets Wilson disease, a rare genetic disorder with significant unmet medical needs
2 more takeaways
Related Filings (3)
3 more filings from Monopar Therapeutics Inc. in the last 90 days
Filing Overview
Form Type8-K
Filing DateJul 22, 2026
Item7.01
CategoryReg FD Disclosure
CIK0001645469
Accession #mnpr20260721_8k.htm
Risk LevelMEDIUM
SentimentPositive
Signalopportunity
Topics
product launchregulatory
What This Means
The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.